FDA Approves Dupixent for Bullous Pemphigoid

FDA Approves Dupixent for Bullous Pemphigoid

drugs.com - 17:48

TUESDAY, June 24, 2025 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous...

Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

drugs.com - 20/Jun 00:06

TARRYTOWN, N.Y. and PARIS, June 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S....

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

zacks.com - 20/Jun 13:46

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

drugs.com - 23/Jun 19:54

MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with...

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

drugs.com - 23/Jun 19:54

MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with...

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

drugs.com - 11/Jun 23:06

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a...

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

drugs.com - 11/Jun 23:06

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a...

FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema

drugs.com - 16/Jun 06:06

KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL today announced the U.S. Food and Drug Administration (FDA)...

FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema

drugs.com - 16/Jun 06:06

KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL today announced the U.S. Food and Drug Administration (FDA)...

Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (ustekinumab-stba), Expanding Dosing Options for Pediatric Patients

drugs.com - 15/Jun 21:06

INCHEON, South Korea, June 15, 2025 -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new...

Rubriques :

FDA Approves Dupixent for Bullous Pemphigoid

Articles similaires

FDA Approves Dupixent for Bullous Pemphigoid

Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema

FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema

Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (ustekinumab-stba), Expanding Dosing Options for Pediatric Patients

Les derniers communiqués